Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 13/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 12/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17437312 | 0.95 | KDM4E (0.34) | CYP11B2CYP11B1RXFP1ALDH1A1ALOX15 | |
| SCHEMBL17437486 | 0.89 | SLC9A1 (0.33) | CYP11B2CYP11B1CYP3A4CYP1A2ALDH1A1 | |
| SCHEMBL17437480 | 0.84 | KDM4E (0.34) | CYP3A4CYP1A2ALDH1A1ALOX15 | |
| SCHEMBL17437512 | 0.83 | CYP11B2 (0.34) | CYP11B2PDE10A | |
| SCHEMBL17437313 | 0.81 | MAPT (0.34) | CYP3A4CYP1A2ALDH1A1TSHRCYP2C19 | |
| SCHEMBL17437394 | 0.81 | CYP1A2 (0.33) | CYP11B2CYP11B1CYP3A4CYP1A2ALOX15 | |
| SCHEMBL17437460 | 0.80 | RPS6KA5 (0.34) | PDE10ACYP1A2 | |
| SCHEMBL17437330 | 0.79 | ADORA3 (0.32) | CYP3A4CYP1A2ALDH1A1CYP2C19 | |
| SCHEMBL17437537 | 0.79 | CYP3A4 (0.36) | CYP11B2CYP11B1CYP3A4CYP19A1CYP1A2 | |
| SCHEMBL17437573 | 0.78 | TLR8 (0.36) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170050963-A1 | MICROBICIDALLY ACTIVE IMIDAZOPYRIDINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-02-23 | — | — | US | disclosed |
| US-9512120-B2 | Microbicidally active imidazopyridine derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2016-12-06 | — | — | US | disclosed |
| US-20160016949-A1 | MICROBICIDALLY ACTIVE IMIDAZOPYRIDINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050963-A1 | MICROBICIDALLY ACTIVE IMIDAZOPYRIDINE DERIVATIVES | IDO1, IDO2, FOXM1 | CYP11B2 1464/4885CYP11B1 1360/4885RXFP1 3140/4885 |
| US-20160016949-A1 | MICROBICIDALLY ACTIVE IMIDAZOPYRIDINE DERIVATIVES | IDO1, IDO2, FOXM1 | CYP11B2 1464/4885CYP11B1 1360/4885RXFP1 3140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.